Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PneumRx Inc.

This article was originally published in Start Up

Executive Summary

From two of the people that founded Spinal Concepts Inc., one of the most successful medical device exits of 2003, comes PneumRx Inc., a new company founded to develop a portfolio of products for interventional pulmonology and thoracic surgery.

You may also be interested in...



Tenaxis Medical Inc.

With a novel biomaterial that can be formulated into specialized products across a broad range of surgical applications, Tenaxis Medical Inc. aims to deliver on the initial promise of sealants to reduce procedure times, increase patient throughput, and improve the quality of patient care across a broad range of surgeries.

Tenaxis Medical Inc.

With a novel biomaterial that can be formulated into specialized products across a broad range of surgical applications, Tenaxis Medical Inc. aims to deliver on the initial promise of sealants to reduce procedure times, increase patient throughput, and improve the quality of patient care across a broad range of surgeries.

Lung Cancer: An Up and Coming Device Market

Lung cancer is the number one cause of deaths from cancer, in large part because it generally isn't detected until very late stages. At that point, survival rates are low and the only option is radical lung surgery. But now imaging technologies can detect smaller cancers, sooner, and in the wake of the publication of the Early Lung Cancer Action Project, the medical device industry is preparing for a paradigm shift. Start-ups are now developing technologies to remove the barriers in diagnosis and access that hinder therapeutic intervention.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037391

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel